Treating inflammatory bowel disease (IBD) with tumor necrosis factor (TNF) inhibitors was paradoxically associated with an increased risk for other immune-mediated inflammatory diseases (IMIDs) in a ...

In a propensity score-matched analysis including 754 patients ages 50 and up, use of vedolizumab was associated with a 45.4% risk of treatment failure -- defined as a composite risk of IBD-related ...

Use of lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) to predict relapse in patients with diffuse large B-cell lymphoma (DLBCL). Background: Inflammatory bowel disease ...

Please provide your email address to receive an email when new articles are posted on . Mirikizumab, a monoclonal antibody poised to become first-in-class treatment for ulcerative colitis, has the ...

Patients with rheumatoid arthritis (RA) who used tumor necrosis factor (TNF) inhibitors had significantly higher rates of nonmelanoma skin cancer and non-Hodgkin lymphoma. A new report based on ...

Patients with both inflammatory bowel disease (IBD) and obesity starting on new biologic therapies do not face an increased risk for hospitalization, IBD-related surgery, or serious infection, reveals ...

Anti-tumor necrosis factor alpha (TNF-alpha) inhibitors are associated with an increased risk for multiple sclerosis (MS), especially among patients with rheumatic disease (RD), new research shows.

While noting that providers and their patients should be aware of the potential risk, the researchers underscored that the risk of new-onset psoriasis due to tumor necrosis factor-α inhibitor (TNFi) ...

Biomedical scientists at the University of California, Riverside, propose a way for drugs to be more effective against inflammatory bowel disease, or IBD, in which the intestine undergoes inflammation ...

Medically reviewed by Shadi Hamdeh, MDMedically reviewed by Shadi Hamdeh, MD Humira (adalimumab) side effects may include pain, irritation, swelling, or itching at the site of the injection, as well ...